Antibody-drug Conjugates Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight

The antibody-drug conjugates market is anticipated to surge as several pharma companies across the globe are thoroughly working toward the development and expansion to treat a wide array of indications such as non-small lung cancer, breast cancer, gynecological cancer, hematologic malignancies, and solid tumors.

LAS VEGAS, April 10, 2023 /PRNewswire/ -- DelveInsight's Antibody-drug Conjugates Market Insights report delivers an in-depth understanding of the ADCs and the antibody-drug conjugates market trends in the 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Antibody-drug Conjugates Market Report

• As per DelveInsight analysis, the antibody-drug conjugates market is expected to grow positively owing to several underline factors during the study period (2019–2032).
• Leading antibody-drug conjugates companies such as ImmunoGen, Daiichi Sankyo, AstraZeneca, Seagen, Sorrento Therapeutics, Inc., Mythic Therapeutics, Merck KGaA, NBE-Therapeutics AG, Gilead Sciences, Regeneron Pharmaceuticals, Kirilys Therapeutics Inc., Tanabe Research Laboratories USA Inc, Sutro Biopharma, Inc., OBI Pharma, Inc, MediLink Therapeutics (Suzhou) Co., Ltd., TORL Biotherapeutics, LLC, Ambrx, Inc., and others are developing novel antibody-drug conjugates that can be available in the antibody-drug conjugates market in the coming years.
• Some key therapies for antibody-drug conjugate treatment include Mirvetuximab Soravtansine, Datopotamab deruxtecan, Ladiratuzumab vedotin, STI-6129, MYTX-011, M1231, NBE-002, Sacituzumab Govitecan, IMGN151, IMGC936, REGN5093-M114, ASN004, TR1801-ADC, STRO-001, OBI-999, YL201, TORL-2-307-ADC, ARX788, and others.
• Several antibody-drug conjugates are awaiting approval, while some ADCs are in the advanced stages of development. 
• In June 2022, a Phase III clinical trial of Datopotamab deruxtecanfor the first-line treatment for triple-negative breast cancer (TNBC) was initiated by Daiichi Sankyo.
• In May 2022, ImmunoGen announced that the FDA had accepted the BLA for Mirvetuximab Soravtansine under Priority Review designation for patients with folate receptor α–high platinum-resistant ovarian cancer.

Discover which ADCs are expected to grab the major antibody-drug conjugates market share @ Antibody-drug Conjugates Market Report

Antibody-drug Conjugates Overview

Antibody-drug Conjugates (ADCs) comprises three main parts: an antibody, a linker, and a payload. The properties of all three components determine the clinical properties of ADCs. The fundamental approach to designing and building ADCs has remained constant since their inception. ADCs have a complex mechanism of action, frequently requiring drug internalization followed by intracellular processing and payload release. Unlike many standard oncology therapies, ADCs must be acted on by cancer cells to be effective. ADCs have both on-target and off-target toxicities; while most toxicities appear to be related to the nature of the payload, there are notable examples of target-dependent toxicities. 

As an ideal delivery platform, ADCs use antibodies as carriers to selectively deliver small molecules to the target, which is typically followed by efficient internalization and subsequent intracellular drug release. It should be noted that ADCs are typically described as targeting antigen-positive cells. However, ADCs only create selective exposure to the target cells upon injection. Overall, selectively exposing small molecules to the desired targets significantly improves the payload's therapeutic index.

Learn more about antibody-drug conjugates for cancer therapy @ Antibody-drug Conjugates Immunotherapy

Antibody-drug Conjugates Market Insights

ADCs are becoming more prevalent in the oncology landscape. More than 10 ADCs are currently on the market for hematological and solid tumor malignancies, with 7 gaining regulatory approval since 2019. In 2000, Pfizer approved gemtuzumab ozogamicin (MYLOTARG), an anti-CD33 mAb-calicheamicin conjugate and the first ADC for oncology for relapsed CD33+ acute myeloid leukemia (AML). The drug was withdrawn from a Phase III trial in 2010 due to toxicity and lack of efficacy, but the FDA approved a lower, fractionated dose in 2017. This medication is also approved in Japan and Europe.

Brentuximab vedotin (ADCETRIS, Seagen/Takeda), the second ADC to enter the oncology market, is a CD30-specific mAb linked to monomethyl auristatin E (MMAE). It is approved in the United States, Europe, and Japan for the treatment of Hodgkin lymphoma and anaplastic large-cell lymphoma. In addition, two ADCs that target CD22 have been approved: inotuzumab ozogamicin (BESPONSA, Pfizer) for relapsed/refractory (R/R) acute lymphoblastic leukemia and moxetumomab pasudotox (LUMOXITI, AstraZeneca/Innate Pharma) for R/R hairy cell leukemia.

Aside from this, two other ADCs with novel targets have been approved: polatuzumab vedotin (POLIVY, Roche) and belantamab mafodotin (BLENREP, GlaxoSmithKline). Polatuzumab vedotin is approved for patients with R/R diffuse large B cell lymphoma and delivers MMAE to B cells expressing CD79b (DLBCL). Belantamab mafodotin is an approved treatment for patients with R/R multiple myeloma that targets BCMA (also known as TNFRSF17).

To know more about antibody-drug conjugates treatment, visit @ Antibody-drug Conjugates Analysis

Key Antibody-drug Conjugates Drugs and Companies

• Mirvetuximab Soravtansine: ImmunoGen
• Datopotamab deruxtecan: Daiichi Sankyo/AstraZeneca
• Ladiratuzumab vedotin: Seagen
• STI-6129: Sorrento Therapeutics, Inc.
• MYTX-011: Mythic Therapeutics
• M1231: Merck KGaA
• NBE-002: NBE-Therapeutics AG
• Sacituzumab Govitecan: Gilead Sciences
• IMGN151: ImmunoGen, Inc.
• IMGC936: ImmunoGen, Inc.
• REGN5093-M114: Regeneron Pharmaceuticals
• ASN004: Kirilys Therapeutics Inc.
• TR1801-ADC: Tanabe Research Laboratories USA Inc
• STRO-001: Sutro Biopharma, Inc.
• OBI-999: OBI Pharma, Inc
• YL201: MediLink Therapeutics (Suzhou) Co., Ltd.
• TORL-2-307-ADC: TORL Biotherapeutics, LLC
• ARX788: Ambrx, Inc.

Learn more about the FDA-approved antibody-drug conjugates @ Approved Antibody-drug Conjugates Treatment 

Antibody-drug Conjugates Market Dynamics

The dynamics of the antibody-drug conjugates market are anticipated to change as companies across the globe are thoroughly working toward the development and expansion to treat a wide array of indications. Moreover, increased tumor specificity and selectivity leading to improved drug tolerability and reduced systemic exposure. Because of the increased tolerability and safety linker chemistry provides, higher doses of toxin-carrying ADCs can be administered to patients, resulting in increased therapeutic efficacy while minimizing side effects, thus propelling the antibody-drug conjugates market growth. Furthermore, the potential for ADCs to demonstrate significant improvement over existing therapies or to address unmet needs makes them prime candidates for Fast Track Designation, Breakthrough Therapy, Priority Review, or other accelerated approval pathways. Because of the increased number of approved ADCs, ADCs are becoming mainstream therapies for various cancer indications.

However, several factors are impacting the growth of the antibody-drug conjugates market. ADCs are still susceptible to resistance and thus have a limited duration of efficacy. When attempting to characterize ADCs made using heterogeneous conjugation approaches, determining the location and number of conjugated payloads can be difficult. ADC development needs to be improved, such as pharmacokinetic complexity, insufficient tumor targeting and payload release, and drug resistance. ADCs also have a high manufacturing cost, which adds to the final cost. Hence, these factors may hamper the growth of the antibody-drug conjugates market in the coming years.

Scope of the Antibody-drug Conjugates Market Report

• Therapeutic Assessment: Current Marketed and Emerging Antibody-drug Conjugates 
• Antibody-drug Conjugates Market Dynamics: Attribute Analysis of Emerging Antibody-drug Conjugates 
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Antibody-drug Conjugates Market Access and Reimbursement

Discover more about antibody-drug conjugates in clinical development @ Antibody-drug Conjugates in Clinical Trials

Table of Contents

Related Reports

Multiple Myeloma Market

Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others.

Multiple Myeloma Pipeline

Multiple Myeloma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others.

Refractory Multiple Myeloma Market

Refractory Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key refractory multiple myeloma companies, including Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, among others.

Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute myeloid leukemia companies, including Takeda Oncology, Immunity Bio, Teva Pharmaceuticals, among others.

Acute Lymphocytic Leukemia Pipeline

Acute Lymphocytic Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute lymphocytic leukemia companies, including AbbVie, Novartis, Jazz Pharmaceutical, among others.

Other Trending Reports

Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market 

Related Healthcare Blogs

Insights into the Evolving Landscape of Antibody-Drug Conjugates

Antibody-Drug Conjugates Market Outlook

Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy

Antibody-Drug Conjugate: The Smart Biological Bomb

ENHERTU's Journey in Cancer Treatment and Management

Antibody-Drug Conjugate and Big Pharmaceutical Companies

Next Generation Antibody-Drug Conjugate Therapeutics and Market Analysis

Related Cases Studies

Competitive Intelligence

Market Assessment

Product Assessment

Epidemiology Assessment

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us :
Shruti Thakur  
info@delveinsight.com  
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg